ProtoKinetix Inc. (PKTX.OB) Adds New Board Member

2/26/2015 11:52:08 AM

VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCQB:PKTX) (www.protokinetix.com) today announced that Peter K. Jensen, LL.B., BCL, B.Sc., Chairman of RepliCel Life Sciences and practicing lawyer, was appointed to the company's board of directors. The Company has also issued 1,000,000 shares of common stock of the Company and a three-year option for 1,000,000 shares of common stock exercisable at $0.05US per share to Mr. Jensen in connection with his appointment to the Board and for services to the Company.

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.